Clinical Trials Logo

Pulmonary Thromboembolisms clinical trials

View clinical trials related to Pulmonary Thromboembolisms.

Filter by:

NCT ID: NCT03134820 Completed - Cancer Clinical Trials

Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease

Start date: December 15, 2015
Phase: N/A
Study type: Observational

Cancer is the most important acquired risk factor of thromboembolisms. More than 20% of all episodes of venous thromboembolism (VT) or pulmonary thromboembolisms (PT) are cancer related. Cancer patients with VT or PT are treated with low molecular weight heparins (LMWH) during at least 3 months, but nowadays the duration of treatment is not accurately determined. The D-Dimer determination has been used like recurrence predictors after LMWH treatment suspension, but in cancer patients the useful is limited. Phospholipid-dependent microparticles could been used like recurrence predictors in cancer patients and tailored the duration of LMWH treatment for each patient.

NCT ID: NCT01531829 Recruiting - Pulmonary Embolism Clinical Trials

Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD

Start date: July 2009
Phase: Phase 4
Study type: Interventional

In selected patients with acute pulmonary embolism(PE), low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) regimen had been reported to have less bleeding tendency than the FDA-approved rt-PA 100mg/2h regimen 100mg/2h regimen (3% vs.10%), it is worthwhile to reveal whether low dose rt-PA plus low molecular weight heparin (LMWH) can rapidly reverses RV pressure overload in PE, but not increase bleeding and other adverse events. The aim of the study is to compare thrombolytic treatment with LMWH in patients with acute normotensive PE with right ventricular dysfunction(RVD).